- Home
- CTMX vs ACOG Comparison
CTMX vs ACOG Comparison
Compare CTMX & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- ACOG
- Stock Information
- Founded
- CTMX 2008
- ACOG 2000
- Country
- CTMX United States
- ACOG Canada
- Employees
- CTMX N/A
- ACOG N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- ACOG
- Sector
- CTMX Health Care
- ACOG
- Exchange
- CTMX Nasdaq
- ACOG Nasdaq
- Market Cap
- CTMX 85.3M
- ACOG 91.6M
- IPO Year
- CTMX 2015
- ACOG N/A
- Fundamental
- Price
- CTMX $0.79
- ACOG $5.88
- Analyst Decision
- CTMX Buy
- ACOG
- Analyst Count
- CTMX 6
- ACOG 0
- Target Price
- CTMX $5.77
- ACOG N/A
- AVG Volume (30 Days)
- CTMX 814.8K
- ACOG 122.5K
- Earning Date
- CTMX 03-10-2025
- ACOG 11-15-2024
- Dividend Yield
- CTMX N/A
- ACOG N/A
- EPS Growth
- CTMX N/A
- ACOG N/A
- EPS
- CTMX 0.16
- ACOG N/A
- Revenue
- CTMX $126,617,000.00
- ACOG N/A
- Revenue This Year
- CTMX $22.55
- ACOG N/A
- Revenue Next Year
- CTMX N/A
- ACOG N/A
- P/E Ratio
- CTMX $4.85
- ACOG N/A
- Revenue Growth
- CTMX 33.66
- ACOG N/A
- 52 Week Low
- CTMX $0.78
- ACOG $4.66
- 52 Week High
- CTMX $5.85
- ACOG $7.00
- Technical
- Relative Strength Index (RSI)
- CTMX 39.47
- ACOG N/A
- Support Level
- CTMX $0.82
- ACOG N/A
- Resistance Level
- CTMX $0.98
- ACOG N/A
- Average True Range (ATR)
- CTMX 0.07
- ACOG 0.00
- MACD
- CTMX 0.00
- ACOG 0.00
- Stochastic Oscillator
- CTMX 6.67
- ACOG 0.00
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a commercial-stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), for which there are currently no approved treatment options.